Cagrilintide + Sema
Investigational — Human trials in progressWhat it is
A combination of the amylin analogue cagrilintide with semaglutide, studied as a dual approach to appetite and glucose. Investigational combination.
A combination of cagrilintide (amylin analogue) and semaglutide (GLP-1 agonist), studied together as a dual approach to appetite and glucose. Investigational as a combination.
Research context
Studied in relation to:
- Appetite and weight research (trial-stage)
Points in its favour in the literature:
- Combines two studied mechanisms
- Emerging trial interest
Caveats and unknowns:
- Investigational combination
- Compounded effects and risks
- No approved equivalent
Handling & reference data
Route in published researchSubcutaneous injection is the route most commonly described in the research literature. Once-weekly in the trials.
Reported half-lifelong-acting, weekly
Published clinical / research context (not instructions)Studied around ~2.4 mg of each component once weekly (trial-stage). Two active agents in one vial — effects and risks combine.
Storage (lyophilised)Lyophilised (freeze-dried) powder: refrigerate at 2–8 °C short-term, or freeze at −20 °C or below for long-term storage. Keep sealed and out of light.
Reconstituted solutionOnce reconstituted: keep refrigerated (2–8 °C), protect from light, do not freeze. With bacteriostatic water, commonly used within ~4 weeks; with plain sterile water, within ~24–48 h.
Worked reconstitution example (arithmetic only)Reconstitute by total peptide, e.g. 10 mg total + 2 mL → 5 mg/mL combined.
Available research formats
| Strength | SKU |
|---|---|
| 5mg+5mg | CS10 |
Current pricing (THB with USD/GBP conversion) is shown live in the catalogue, which also has a transparent U-100 reconstitution calculator.